A Phase 2a trial testing foralumab nasal spray in people with nonactive SPMS has dosed the first patients enrolled at Yale MS ...

Gilead’s $11.9 billion purchase of Kite Pharma in 2017 didn’t follow the script, with two big write-downs in the value of the asset since then, but a fresh approval for a CAR-T therapy could ...

I’m back from another week in San Francisco, where as usual I heard from experts and prognosticators about their expectations for the coming year in biotech. But this year prognostication was in ...